hypothesized that Alzheimer’s is caused by an amyloid beta (Aβ) protein known as Aβ*56. Aβ proteins have long been thought to contribute to Alzheimer’s. Ashe’s study asserted that “Aβ ...

This mechanism, which involves extracellular accumulation of a 56 kDa soluble amyloid-β (Aβ) assembly, dubbed Aβ*56, has been shown to induce memory deficit in middle-aged Tg2576 MICE ...

A team of scientists including UCL researchers has tested four anti-amyloid Alzheimer's therapeutics to find out how the ...

The test, known as AD-Detect Abeta 42/40 and p-tau217 Evaluation, is said to combine amyloid beta (AB) 42/40 blood level outcomes, which are determined by Quest’s tandem mass spectrometry techniques ...

There’s evidence in people and animals that short-term sleep deprivation can change the levels of amyloid-β, a peptide that can accumulate in the aging brain and cause Alzheimer’s disease. Scientists ...

Panelists discuss how managing patients with mild cognitive impairment using amyloid-targeting therapies faces significant barriers including limited healthcare infrastructure for complex diagnostic ...

Although there are many outstanding questions about Alzheimer’s and a significant lack of effective drugs, scientists believe a protein called amyloid-beta plays an important role in the condition.

March 26, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta ...

Jürgen Götz, from UQ’s Queensland Brain Institute (QBI), says the recent FDA approval of amyloid-beta antibodies for treating early-stage Alzheimer’s disease in humans is encouraging but ...